Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy.

Similar documents
Thrombus Aspiration before PCI: Routine Mandatory. Professor Clinical Cardiology Academic Medical Center University of Amsterdam

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN

Trial Update- TOTAL. Jonathan Byrne

Revived indications for thrombus aspiration during primary PCI: Unanswered questions after TAPAS

SYSTEMATIC MANUAL THROMBUS ASPIRATION: PRO

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

M/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

When Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E

Updated and Guideline Based Treatment of Patients with STEMI

ΟΜΑΔΕΣ ΕΡΓΑΣΙΑΣ ΘΕΣ/ΝΙΚΗ 2013

No-reflow is defined as a failure to restore antegrade normal coronary flow despite appropriate treatment of coronary obstruction. The prevalence of t

Cover Page. The handle holds various files of this Leiden University dissertation

ACI London Thrombectomy in STEMI. is the evidence clear? Brad Higginson International marketing manager

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

PCI Update Qesaria 2009

LM stenting - Cypher

A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI

PROMUS Element Experience In AMC

FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention

TCT mdbuyline.com Clinical Trial Results Summary

STEMI Primary Percutaneous Coronary Intervention

Clinical Considerations for CTO

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

The Japanese ASPARAGUS Trial

Preprocedural TIMI Flow and Mortality in Patients With Acute Myocardial Infarction Treated by Primary Angioplasty

International Journal of Cardiology and Cardiovascular Research Vol. 1(1), pp , June,

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Percutaneous Intervention of Unprotected Left Main Disease

Unprotected LM intervention

Supplementary Table S1: Proportion of missing values presents in the original dataset

Recurrent Thrombosis in a Case of Coronary Ectasia with Large Thrombus Burden Successfully Treated by Adjunctive Warfarin Therapy

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

CORONARY CHRONIC TOTAL OCCLUSIONS IN THE SETTING OF ACUTE MYOCARDIAL INFARCTION

Bivalirudin Clinical Trials Update Evidence and Future Perspectives

Therapeutic Advances in Cardiology

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

Ventricular Arrhythmias in Acute MI Patients Undergoing Primary PCI

Primary PCI in patients with STEMI Abbott Vascular. All rights reserved.

Prevention of Coronary Stent Thrombosis and Restenosis

Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction

Cardiogenic Shock. Carlos Cafri,, MD

FFR-guided Jailed Side Branch Intervention

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller

Frans Van de Werf, MD, PhD Leuven, Belgium

Approach to Multi Vessel disease with STEMI

Α-Δ. ΜΑΤΡΟΓΙΑΝΝΗ ΚΑΡΔΙΟΛΟΓΟ AIMOΔΤΝΑΜΙΚΟ ΕΡΓΑΣΗΡΙΟ Γ.Ν.Θ. Γ. ΠΑΠΑΝΙΚΟΛΑΟΤ ΘΕΑΛΟΝΙΚΗ

Optimal antithrombotic therapy:

Lessons learned From The National PCI Registry

Cafri C; Zahger D; Rosenshtein G, Kleshian I; Ilia R

Assessment of plaque morphology by OCT in patients with ACS

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Coronary interventions

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany

GENNARO SARDELLA MD, FACC,FESC

Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

Journal of the American College of Cardiology Vol. 55, No. 9, by the American College of Cardiology Foundation ISSN /10/$36.

AngioJet Rheolytic Thrombectomy During Rescue PCI for Failed Thrombolysis: A Single-Center Experience

DECLARATION OF CONFLICT OF INTEREST

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Bifurcations Bad Krozingen I

1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.

Side Branch Occlusion

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Management of Cardiogenic shock. Prof. Christian JM Vrints

MULTIcentre evaluation of Single high-dose. acute myocardial infarction study

PCI for Left Anterior Descending Artery Ostial Stenosis

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

Annie Chou Internal Medicine PGY3 University of British Columbia. Rocky Mountain Internal Medicine Conference November 24, 2011

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Georgios Pavlakis. Consultant Interventional Cardiologist. K.A.T. General Hospital of Athens, GREECE

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Coronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress test results

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Pharmaco-Invasive Approach for STEMI

IABP SHOCK II trial:

CLINICAL CONSEQUENCES OF THE

Management of Acute Myocardial Infarction

THE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION

New Double Stent Technique

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Intraluminal Thrombus in Facilitated Versus Primary Percutaneous Coronary Intervention

STEMI AND MULTIVESSEL CORONARY DISEASE

PCI for Chronic Total Occlusions

Primary Percutaneous Coronary Intervention

TRIAS HR Pilot Study

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Clinical Considerations for CTO Revascularization

Journal of the American College of Cardiology Vol. 56, No. 16, by the American College of Cardiology Foundation ISSN /$36.

Transcription:

Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy. GENNARO SARDELLA, MD, FACC,FESC; MASSIMO MANCONE, MD; RAFFAELE SCARDALA, MD; ANGELO DI ROMA,MD; LORENZO MARIA ZUCCARO, MD; GIULIA BENEDETTI, MD; GIULIA CONTI,MD ; FRANCESCO FEDELE, MD. O.U. of Invasive Cardiology, Dept. of Cardiovascular Sciences Policlinico Umberto I Sapienza University of ROME

GENNARO SARDELLA MD Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy. FINANCIAL DISCLOSURE: No relationship to disclose

Cumulative Survival (%) Background In the AMI setting the distal embolization after the IRA reopening ( no-flow phenomenon) is associated with poor perfusion and high mortality. 100 Final Blush Score (patients with final TIMI 3 flow) 95 3 OOPS!! 90 85 80 Blush 1-Year Mortality 3 2 0/1 6.8% 13.2% 18.3% P=0.004 75 0 2 4 6 8 10 12 2 0/1 Myocardial Perfusion (MBG) After Primary PCI is the Strongest Predictor of Mortality independently from IRA reopening Stone GW, et al. J Am Coll Cardiol. 2002;39:591-597.

Sep 5. [Epub ahead of print] Background PPCI Hardest point Open Artery...but Closed Myocardium!! MBG 3 30 Day mortality Favours Control Favours Thrombectomy Favours Thrombectomy Favours Control (De Luca G.,Dudek D. Sardella G. et al EHJ 2008 Sep 5. [Epub ahead of print])

DIP.di SCIENZE CARDIOVASCOLARI Impact of thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI. ( EXPIRA Trial ). A Prospective, Randomized Trial of Thromboaspiration during Primary Angioplasty in Acute Myocardial Infarction Principal Investigator : G. SARDELLA MD, FACC, FESC Investigators : M.Mancone, A.Di Roma, L.De Luca, G.Conti, R.Colantonio, G.Benedetti. O.U. of Invasive Cardiology, Dept. of Cardiovascular Sciences Policlinico Umberto I - University La Sapienza ROME

Design Prospective, randomized, double-arm, mono-centric study. Primary end-point : Final MBG 2 ; 90 ST resolution Impact of Thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI ( EXPIRA Trial ). (G.Sardella et al. TCT 2007) (> 70% decrease of ST segment after PCI) Secondary end-point : MACE at 9 month clinical f-u Principal investigator G.Sardella MD 256 pts. (STEMI, at 6.8 ± 2.3 h from symptoms onset) 175 pts. eligible for 1:1 randomization 88 pts randomized to Thrombectomy + PCI (Heparin 7.500 U/I, GPIIb/IIIa, Aspirin, Clopidogrel 300 mg) 81 pts.excluded: Cardiogenic shock 3-vessel / Left Main TIMI >0-1 TS < 3 87 pts randomized to Standard PCI Contra to GPIIb/IIIa Final MBG 2 ; 90 ST resolution 9 months clinical f-u

Methods Inclusion Criteria Age >18 yrs STEMI within 9 hrs from symptoms onset De novo coronary artery lesions Native IRA 2.5 mm diameter Angiographically identifiable occlusive thrombus (TS grade 3) TIMI 0-1 at time of initial angiography Exclusion Criteria Previous AMI or CABG Cardiogenic shock 3-vessel / Left Main CAD Severe valvular heart disease Unsuccessful PCI (no antegrade flow or 50% residual stenosis in the IRA) Rescue / Facilitaded PCI Contraindication to GP IIb/IIIa inhibitors

Impact of Thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI ( EXPIRA Trial ). 1 Primary End-point MYOCARDIAL BLUSH GRADE % 100 90 80 70 60 50 40 30 20 10 0 Basal Final Basal Post-Thr. Final Post- POBA CONVENTIONAL GROUP 28.7* 39.5* *p=<0.0001 EXPORT GROUP (G.Sardella et al,tct 2007) 70.3* 11.8* MBG 3 MBG 2 MBG 0/1

Impact of Thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI ( EXPIRA Trial ). 2 Primary End-point 90 ST resolution after PCI (%) ( > 70% decrease of ST segment) p=<0.01 % 100 90 80 70 60 50 40 30 20 10 0 37.5 OR 6.36 (95% CI 3.23-12.50) 80.0 CONVENTIONAL GROUP EXPORT GROUP (G.Sardella et al,tct 2007)

Pts % 12 10 8 6 4 Impact of Thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI ( EXPIRA Trial ). 9 months Composite Cardiac Event Rates log-rank p=0.02 4,6 10,3 p=ns 4,5 CONTR. EXPORT 2 0 DEATH 0 MACE (G.Sardella et al,tct 2007)

EXPIRA Trial MRI Study Design Prospective, randomized, double-arm, mono-centric study. 1 End-points (MRI evaluation) 75 patients eligible for 1:1 randomization (Anterior STEMI, at 6.8 + 2.3 h from symptoms onset) (Heparin 7.500 U/I, GPIIb/IIIa, Aspirin, Clopidogrel 300 mg) Microvascular damage (grams/g) in terms of Hypoenhancement. Infarct size (grams/g) in terms of Hyperenhancement. 37 pts randomized to Standard PCI 38 pts randomized to Thrombectomy + PCI 3 90 Day MRI follow-up (G.Sardella et al, JACC 2008 in press) Microvascular damage Infarct size

MRI Results 20 p=0.004 18 16 14 P<0.001 gr 12 10 8 6 g 17 ± 15 11 ± 8.7 Standard PCI Thrombectomy 4 2 0 3.7 ± 2.6 1.7±1.9 Hypo 3 Days Hypo 3 Months Hyper 3 Days days Hyper 3 Months (G.Sardella et al, JACC 2008 in press)

Myocardial Function Tissue Doppler imaging (TDI) quantitatively assess regional myocardial function by measuring Systolic Strain, an index reflecting the extent of myocardial fiber deformation. Regional and global strain at 1.5 h after reperfusion therapy correlates with size and transmural extent of myocardial infarction as determined by CE-MRI. (Vartdal T et al. J Am Coll Cardiol 2007;49:1715 21)

EXPIRA Trial TDI Study Aim of the Study We sought to evaluate the impact of thromboaspiration on procedural outcomes and Systolic Strain by TDI as compared to conventional primary PCI Export aspiration catheter (Medtronic, Minneapolis, Minnesota)

Methods Design Prospective, randomized, double-arm, single-centre study. 1 End-point (TDI evaluation): 75 patients eligible for 1:1 randomization (Anterior STEMI, at 6.8 + 2.3 h from symptoms onset) (Heparin 7.500 U/I, GPIIb/IIIa, Aspirin, Clopidogrel 300 mg) LV function recovery evaluated in terms of global and segmental Systolic Strain (%) by TDI 37 pts randomized to Standard PCI 38 pts randomized to Thrombectomy + PCI 12 pts(16%) were not analyzed because of poor echocardiographic quality TDI evaluation 16 segments model was applied and regional myocardial function was evaluated, 90 after primary PCI, by measuring peak systolic myocardial strain by TDI

CLINICAL CHARACTERISTICS Age, yrs±sd Males (%) Risk factors Hypertension (%) Diabetes (%) Smoking (%) Obesity (%) Family History of CAD (%) Cholesterol (mg/dl±sd) Triglycerides (mg/dl±sd) Renal Failure (%) Killip class III (%) Previous PCI (%) Symptoms to balloon, (hrs±sd) Total Population (n=75) 66.3 10.6 47 (62.7) 43 (57.8) 17 (22.7) 26 (34.7) 2 (2.7) 27 (36.0) 164 13 120 35 4 (5.3) 19 (25.3) 10 (13.3) 7.9 0.7 Conventional Group (n=37) 65.8 13.1 24 (64.7) 24 (64.9) 9 (24.3) 11 (29.8) 2 (5.4) 12 (32.4) 165 10 122 23 3 (8.1) 12 (32.4) 4 (10.8) 7.7 1.2 Thrombectomy Group (n=38) 67.4 14.1 23 (60.5) 19 (50.0) 8 (21.1) 15 (39.5) 0 15 (39.5) 163 11 121 27 1 (2.6) 7 (18.4) 6 (15.8) 6.5 1.4 LVEF (%±SD) 43.1 ±12 40.8 ±7.5 41.9 ±0.9 P= ns for all characteristics

PROCEDURAL CHARACTERISTICS 1 MLD pre, mm±sd 0.8 0.4 0.9 0.4 Total Population (n=75) Conventional Group (n=37) IABP (%) 7 (9.3) 4 (10.8) Lesion length, mm±sd 13.8 5.7 14.1 5.6 Vessel size, mm±sd 2.9 0.6 2.8 0.5 GPIIb/IIIa Inhibhitors Direct stenting Post-dilatation MLD post, mm±sd Post-PCI diameter stenosis, (%±SD) Stent Type (%) Bare-metal Stent Drug-eluting Stent Thrombectomy Group (n=38) 3 (7.9) 14.9 4.9 2.9 0.6 0.7 0.3 75 (100) 37 (100) 38 (100) 32 (42.6) 2 (5.4)* 7 (9.3) 2.9 0.7 3 (8.1) 2.8 0.5 28 (74.3) 4 (10.5) 2.9 0.3 3.4 5.2 3.5 3.9 3.4 5.4 29 (38.7) 46 (61.3) 17 (45.9) 20 (54.0) 12 (31.5) 26 (68.4) * 2 pts with recanalized IRA after guide-wire placement p= <.0001

PROCEDURAL RESULTS MYOCARDIAL BLUSH GRADE % 100 90 80 70 60 50 40 30 20 10 0 Basal Post- POBA Final Basal Post-Thr. Final CONVENTIONAL GROUP 32.4* *p=<0.0001 76.3* THROMBECTOMY GROUP MBG 3 MBG 2 MBG 0/1

In-Hospital Outcome % 100 90 80 70 60 50 40 30 20 10 0 90 ST resolution after PCI ( > 70% decrease of ST segment) 40.5 CONVENTIONAL GROUP p=.0001 OR 7.2 (95% CI 2.5-20.9) 84.2 THROMBECTOMY GROUP

TDI Results Mean Systolic Strain P<0.005 % 15.4±4.2% 18.1±3.1%

TDI Results Mean Systolic Strain in Infarcted Area P<0.0001 % 12.2±2.6% 8.8±4.3% Infarcted Segments Non-Infarcted Segments

TDI and MRI Correlation Significant Systolic Strain / Delayed Hyperenhancement correlation (r=0.69; p<0.05) Low HPRE High HPRE

Conclusion In our experience Thrombectomy has been demonstrated to be safe and effective in AMI setting during Primary PCI. Compared with conventional stenting, in well selected patients with intracoronary visible and occlusive thrombus, pretreatment with manual aspiration thrombectomy during primary PCI improves acutely the parameters of myocardial tissue perfusion and ST resolution with a reduction of microvascular damage and infarct size in long term compared with acute evaluation. The difference observed in term of Systolic Strain between the two groups suggest a rapid and better segmental function recovery in pts treated with Thrombectomy. These data also confirm that Systolic Strain after primary PCI could be useful to evaluate if primary percutaneus reperfusion has been effective in terms of function recovery.

Thank You!

PROCEDURAL RESULTS 1 TIMI FLOW GRADE p=0.0005 p=ns 100 90 80 70 60 % 50 40 30 20 10 0 Basal Post POBA CONVENTIONAL GROUP Final Basal Post- Thromb Final THROMBECTOMY GROUP TIMI 3 TIMI 2 TIMI 0/1